Imbria Pharmaceuticals Announces Extension of Series B Financing to Advance Ninerafaxstat for Cardiovascular Diseases
Imbria Pharmaceuticals announced an extension of its Series B financing, now involving AXA IM Alts, to advance ninerafaxstat, a novel therapy for cardiovascular diseases. This funding will support its clinical development amid the global burden of cardiovascular health. New board members, Dr. Zina Affas Besse and Mr. Ken Horne, enhance the company’s expertise.